Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Xtant Medical Holdings, Inc.v385784_ex99-1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

  

Date of report (Date of earliest event reported): August 6, 2014

 

Bacterin International Holdings, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-34951 20-5313323
(Commission File Number)

(IRS Employer Identification No.)

 

600 Cruiser Lane

Belgrade, Montana

59714
(Address of Principal Executive Offices)

(Zip Code)

 

(406) 388-0480

(Registrant’s Telephone Number, Including Area Code) 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

  

Item 8.01Other Events.

 

On August 6, 2014, we completed an underwritten public offering of 1,143,000 shares of our common stock at $5.70 per share and warrants to purchase 571,500 shares of our common stock at an exercise price of $7.12 per share to the public. Northland Securities, Inc. was the sole book-running manager for the offering. Northland Capital Markets is the trade name for certain capital markets and investment banking services of Northland Securities, Inc., member FINRA/SIPC.

 

The shares and warrants were offered and sold pursuant to a prospectus supplement dated August 1, 2014 and an accompanying base prospectus dated March 31, 2014, pursuant to our shelf registration statement on Form S-3 (File No. 333-194944) which became effective on April 8, 2014.

 

On August 6, 2014, we issued a press release announcing the closing of the offering referred to above. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. 

 

Item 9.01.Financial Statements and Exhibits.

 

(d)  Exhibits.

 

Exhibit No   Description
     

99.1

 

  Press Release dated August 6, 2014
 
 

 

SIGNATURE 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:  August 6, 2014 BACTERIN INTERNATIONAL HOLDINGS, INC.  
       
       
       
  By:   /s/ John Gandolfo  
  Name:   John Gandolfo  
  Title:              CFO  

 

 

 

 

 
 

EXHIBIT INDEX

 

99.1

 

  Press Release dated August 6, 2014